The collaborators have signed a two-year research and license option agreement to develop novel T-cell therapies for cancer using genome editing technology.
American Society of Clinical Oncology presentations show the unmet need for methods to predict autoimmune toxicities in checkpoint blockade-treated individuals.
The study will use OncoDNA's liquid biopsy tech to profile and identify treatment options for 100 patients in Lebanon, Jordan, Saudi Arabia, and the UAE.
In Science this week: a survey indicates that US adults are more likely to support the agricultural use of gene drives if they target non-native species and if they are limited, and more.
